

Rapid cell-free characterization of multi-subunit CRISPR effectors and transposons

Franziska Wimmer^{1*}, Ioannis Mougias^{1*}, Frank Englert¹, Chase L. Beisel^{1,2#}

¹Helmholtz Institute for RNA-based Infection Research, Helmholtz Centre for Infection Research, Würzburg, Germany

²Medical faculty, University of Würzburg, Würzburg, Germany

*Equal contributions

#Correspondence to: chase.beisel@helmholtz-hiri.de (to C.L.B.)

1 **ABSTRACT**

2 CRISPR-Cas biology and technologies have been largely shaped to-date by the characterization
3 and use of single-effector nucleases. In contrast, multi-subunit effectors dominate natural
4 systems, represent emerging technologies, and were recently associated with RNA-guided DNA
5 transposition. This disconnect stems from the challenge of working with multiple protein subunits
6 *in vitro* and *in vivo*. Here, we apply cell-free transcription-translation (TXTL) to radically accelerate
7 the characterization of multi-subunit CRISPR effectors and transposons. Numerous DNA
8 constructs can be combined in one TXTL reaction, yielding defined biomolecular readouts in
9 hours. Using TXTL, we mined phylogenetically diverse I-E effectors, interrogated extensively self-
10 targeting I-C and I-F systems, and elucidated targeting rules for I-B and I-F CRISPR transposons
11 using only DNA-binding components. We further recapitulated DNA transposition in TXTL, which
12 helped reveal a distinct branch of I-B CRISPR transposons. These capabilities will facilitate the
13 study and exploitation of the broad yet underexplored diversity of CRISPR-Cas systems and
14 transposons.

15

16 **KEY WORDS**

17 Cascade / CAST / PAM / PAM-DETECT / TXTL / Type I CRISPR-Cas system

18

19 **HIGHLIGHTS**

- 20 ● PAM-DETECT for rapid determination of PAMs for Type I CRISPR-Cas systems in TXTL
- 21 ● Mining of Type I orthologs and characterization of extensively self-targeting systems
- 22 ● TXTL-based assessment of DNA target recognition and transposition by CRISPR
- 23 transposons
- 24 ● Identification of a distinct branch of Type I-B CRISPR transposons

25

26 INTRODUCTION

27 CRISPR-Cas systems endow prokaryotes with adaptive defense against invading elements and
28 possess effector nucleases that have become versatile biomolecular tools (Barrangou and
29 Doudna, 2016; Pickar-Oliver and Gersbach, 2019). These systems are remarkably diverse, with
30 two classes, six types, over 30 subtypes, and a few subtype variants defined to-date (Makarova
31 et al., 2019). The two classes are distinguished based on whether the effector nuclease
32 responsible for CRISPR RNA (crRNA)-directed immune defense comprises a multi-protein
33 complex (Class 1) or a single multi-domain protein (Class 2). While systems from both classes
34 have undergone characterization, Class 2 systems have been the most extensively explored. For
35 example, comprehensive determination of target-flanking protospacer-adjacent motifs (PAMs)
36 (Leenay and Beisel, 2017) has been conducted for more than 100 Class 2 effectors spanning at
37 least 15 subtypes (Collias and Beisel, 2021); in contrast, only for 10 Class 1 effectors spanning 7
38 subtypes (**Table S1**). This discrepancy belies the unique features of Class 1 systems that have
39 attracted increasing attention for basic research and technology development (Hidalgo-
40 Cantabrana and Barrangou, 2020). Class 1 systems represent over 75% of all CRISPR-Cas
41 systems found in nature and contain phylogenetically diverse proteins possessing unique
42 mechanisms of action (Makarova et al., 2015). The associated machinery has also been recently
43 applied as tools in mammalian and plant cells, offering distinct means of achieving programmable
44 gene regulation and genome editing as well as the creation of variable chromosomal deletions
45 (Liu et al., 2018; Zheng et al., 2020). The same machinery has also been associated with
46 emerging alternative functions in bacteria, such as repressing expression of a toxin to promote
47 selection of the CRISPR-Cas system or to counter infection by phages encoding an inhibitory
48 anti-CRISPR protein (Acr) (Li et al., 2021). Finally, a subset of Class 1 systems contain Tn7-like
49 transposon genes and were shown to mediate crRNA-directed transposition (Klompe et al., 2019;
50 Petassi et al., 2020; Peters et al., 2017; Saito et al., 2021). These CRISPR transposons (CASTs)
51 have since been employed in bacteria for the efficient, programmable, and multiplexed insertion

52 of donor DNA exceeding 10 kb (Klompe et al., 2019; Strecker et al., 2019; Vo et al., 2021). The
53 examples noted above highlight the potential of further exploring and harnessing Class 1
54 CRISPR-Cas systems and CASTs.

55 The disconnect between the broad relevance of Class 1 systems and the few well-
56 characterized examples can be largely attributed to the challenge of working with multiple protein
57 subunits. Cell-based assays are complicated by the need to encode and optimally express
58 multiple subunits from a minimal number of constructs, while *in vitro* assays require intensive
59 purification of multi-subunit complexes--tasks that are far simpler for single-effector nucleases. A
60 promising alternative came with the advent of cell-free transcription-translation (TXTL) systems
61 and their use for rapidly and scalably characterizing CRISPR-Cas systems (Garamella et al.,
62 2016; Jiao et al., 2021; Liao et al., 2019a, 2019b; Marshall et al., 2018; Maxwell et al., 2018;
63 Silverman et al., 2020; Watters et al., 2018). As part of a TXTL reaction, circular or linear DNA
64 constructs are added to the TXTL mix, resulting in the transcription and translation of the encoded
65 products in minutes to hours. Expressing CRISPR machinery targeted to an included reporter
66 construct further provides a quantitative and dynamic readout based on expression levels and
67 targeting activity. In our prior work, we showed that TXTL could functionally express the Type I
68 effector complex Cascade (CRISPR-associated complex for antiviral defense) that yielded
69 transcriptional repression of a reporter gene (Marshall et al., 2018). However, all other
70 implementations of TXTL to-date have focused on single-effector nucleases (Khakimzhan et al.,
71 2021; Liao et al., 2019a, 2019b; Wandera et al., 2020; Watters et al., 2018). Here, we leverage
72 TXTL to rapidly characterize diverse Type I systems and transposons, allowing ortholog mining,
73 characterization of self-targeting systems, and harnessing of CASTs. The resulting capabilities
74 are expected to accelerate the exploration and exploitation of this broad yet understudied branch
75 of CRISPR biology.

76

77 **RESULTS**

78 **PAM-DETECT: a TXTL-based enrichment assay for PAM determination.** One of the defining
79 features of DNA-targeting CRISPR-Cas systems is the PAM (Leenay and Beisel, 2017). This
80 collection of sequences always flanks a crRNA target and allows the effector nuclease to
81 discriminate between self (the equivalent targeting spacer in the CRISPR array) and non-self (the
82 invader). However, the associated sequences can vary widely even between close homologs
83 (Collias and Beisel, 2021). Given that the comprehensive PAM determination assays applied for
84 Class 1 systems involved laborious *in vitro* or cell-based assays (**Table S1**), we devised a TXTL-
85 based assay that could elucidate the complete PAM profile recognized by an effector complex
86 but without the need for protein purification or cellular expression (**Figs. 1A and B**). The assay
87 involves expressing the crRNA and the three to five Cas proteins that form Cascade, which then
88 binds target DNA. While Cascade binding normally recruits the endonuclease Cas3 to nick and
89 processively degrade the non-target strand of DNA (Huo et al., 2014; Mulepati and Bailey, 2013;
90 Westra et al., 2012), Cascade strongly binds DNA even without Cas3 (Jore et al., 2011; Westra
91 et al., 2012). As part of the TXTL-based assay, Cascade binds target DNA flanked by a library of
92 potential PAM sequences. After sufficient time to produce Cascade and ensure DNA binding, a
93 restriction enzyme is introduced that cleaves a sequence within the DNA target. As a result, DNA
94 containing a recognized PAM sequence is protected by the bound Cascade, thereby enriching
95 this sequence within the library. Next-generation sequencing (NGS) is then performed to quantify
96 the relative frequency of each PAM sequence before and after restriction digestion. We call this
97 assay PAM-DETECT (PAM-DETermination with Enrichment-based Cell-free TXTL). From the
98 addition of the DNA constructs to the isolation of library DNA for NGS, the entire process requires
99 13 to 23 hours -- substantially faster than the days to weeks required for *in vitro* and cell-based
100 assays when starting with DNA expression constructs. Also, because the reactions are conducted
101 in a few microliters, reactions can be conducted in parallel in microtiter plates for characterizing a
102 massive number of systems and conditions at one time.

103 As part of PAM-DETECT, we devised two parallel checkpoints to assess the extent of
104 library protection and PAM enrichment prior to submitting samples for NGS. For the first
105 checkpoint (**Fig. 1C**), qPCR is applied with a digested and undigested library to measure the
106 extent to which the library was protected by Cascade binding. Given that excess effector can
107 boost the prevalence of less-preferred PAM sequences (Karvelis et al., 2015), the qPCR results
108 can indicate the stringency of the determined PAM sequences. Fortunately, the conditions of
109 PAM-DETECT can be readily tuned by changing the concentration of the added DNA constructs
110 and the time allowed for Cascade expression and DNA binding. For the second checkpoint (**Fig.**
111 **1D**), the digested and undigested libraries are subjected to Sanger sequencing. Elevated peaks
112 in the digested sample reflect enrichment of those bases at that PAM position, providing an early
113 indication of the determined PAM.

114

115 **PAM-DETECT validated with the canonical Type I-E CRISPR-Cas system from *Escherichia***
116 ***coli*.** To evaluate PAM-DETECT, we began with Cascade encoded by the Type I-E CRISPR-Cas
117 system from *Escherichia coli* (**Fig. 2A**), the best studied Type I system to-date. As part of its
118 extensive characterization, the effector complex has been subjected to multiple comprehensive
119 PAM determination assays (Caliando and Voigt, 2015; Fineran et al., 2014; Fu et al., 2017;
120 Leenay et al., 2016; Musharova et al., 2019; Xue et al., 2015), establishing a complex landscape
121 principally composed of the canonical PAM sequences AAG, AGG, ATG, and GAG (written 5' to
122 3') located on the non-target strand immediately upstream of the guide sequence. We applied
123 PAM-DETECT by encoding the five Cascade genes and a targeting single-spacer CRISPR array
124 encoding a crRNA on six separate plasmids and combining these plasmids with a 5-base PAM
125 target library in TXTL (**Fig. 2A**). To explicitly evaluate the impact of excess effector complexes,
126 we tested two different conditions: one with 0.25 nM of Cascade-encoding plasmids and 6-hour
127 reaction time for low Cascade expression and binding, and another with 3 nM of Cascade-
128 encoding plasmids and 16-hour reaction time for high Cascade expression and binding. The

129 intermediate qPCR check showed significant DNA protection compared to the control lacking
130 Cascade, with ~2-fold more protection with the high versus low Cascade condition (**Fig. 2B**).
131 Correspondingly, the Sanger sequencing checkpoint showed enrichment of an AAG motif
132 compared to the undigested control, where the motif was more pronounced for the low Cascade
133 condition (**Fig. 2C**). The checkpoints were in line with protection of DNA sequences related to the
134 known PAM, with enhanced protection for the high Cascade condition.

135 Given the promising results from the two checkpoints, we proceeded to NGS with both
136 Cascade conditions to map the full PAM profile. After determining an enrichment score for each
137 library sequence, we visualized the results as a PAM wheel to capture both individual sequences
138 and enrichment scores (Leenay et al., 2016) (**Fig. 2D**). The PAM wheel for the low Cascade
139 condition captured the four known canonical PAMs as well as other well-recognized PAM
140 sequences (e.g. TAG, AAC) reported in prior screens (Caliando and Voigt, 2015; Fineran et al.,
141 2014; Leenay et al., 2016; Musharova et al., 2019; Xue et al., 2015). The PAM wheel for the high
142 Cascade condition included these PAM sequences as well as other PAM sequences that were
143 less enriched (e.g. AAA, AAT) or negligibly enriched (e.g. CAG, ATT) for the low Cascade
144 condition (**Fig. 2D**). The differences in PAM profiles demonstrate how PAM-DETECT can be
145 readily tuned by varying plasmid concentration and reaction time.

146 To validate the results, we applied TXTL to silence expression of a deGFP reporter (Shin
147 and Noireaux, 2012) using a distinct target sequence overlapping the reporter's upstream
148 promoter (**Fig. 2E, Table S2**). The PAM region could then be altered without affecting the
149 promoter sequence. For representative PAM sequences, the fold-repression of deGFP production
150 versus a non-targeting control strongly correlated with the enrichment score of each sequence in
151 PAM-DETECT for the low Cascade condition ($R^2 = 0.99$) (**Fig. 2F**). The correlation was
152 particularly striking given the use of a different target sequence, which can affect the apparent
153 hierarchy of PAM recognition (Leenay et al., 2016; Xue et al., 2015). Applying the same assay to
154 PAM sequences enriched under the high Cascade condition but not detected with our previous

155 PAM-SCANR method (Leenay et al., 2016), we measured modest but significant deGFP
156 repression (**Fig. 2G**). These validation experiments show that PAM-DETECT can produce
157 comprehensive and quantitative PAM profiles, and the assay conditions can be readily altered to
158 tune the stringency of PAM detection.

159

160 **Distinct PAM profiles pervade I-E CRISPR-Cas systems.** After validating PAM-DETECT using
161 the established I-E system from *E. coli*, we turned to the first important use of this assay: mining
162 diverse CRISPR effector proteins and complexes. Nuclease mining has been highly successful
163 for single-effector nucleases such as Cas9, which revealed a wide collection of nucleases
164 recognizing the full spectrum of PAMs (Gasiunas et al., 2020; Zetsche et al., 2020). Nuclease
165 mining therefore could be highly valuable when applied to Class 1 systems. Focusing again on
166 the I-E subtype of CRISPR-Cas systems, we began by identifying diverse Cas8e proteins
167 responsible for PAM recognition within Cascade from known cultured mesophilic bacterial strains.
168 This analysis revealed a set of 213 Cas8e proteins (**Table S3**). We further divided the Cas8e set
169 in groups according to the amino-acid sequence of the highly variable L1 loop within the N-
170 terminal domain (**Table S3**) reported to stabilize the Cas8e-PAM interactions (Tay et al., 2015;
171 Xiao et al., 2017). The numerous clusters with distinct L1 motifs suggested diverse modes of PAM
172 recognition extending beyond that observed with *E. coli*'s Cascade.

173 We selected 11 representative I-E systems reflecting some of the most abundant L1 motifs
174 to characterize with PAM-DETECT (**Figs. 3A, S1**). Characterizing the resulting Cascade
175 complexes required encoding 55 Cascade genes and 11 single-spacer arrays, each in separate
176 plasmids. However, despite this large number of constructs, PAM-DETECT could be performed
177 with all constructs in parallel. We selected the high Cascade conditions (3 nM plasmids, 16 hour
178 reaction time) given uncertainty about how well a given system would be functionally expressed
179 in TXTL. All but one system yielded significant enrichment of the PAM library compared to a non-
180 digested control (**Fig. S1A**), allowing us to determine a large number of PAM profiles.

181 PAM-DETECT revealed a broad range of recognized PAMs (**Figs. 3A, S1B**). The PAM
182 profile most distinct from that associated with the *E. coli* Cascade was recognized by Cascade
183 from *Streptococcus thermophilus* DGCC 7710 (Sth), which recognized any sequence with an A
184 or T at the -1 position as well as AS (S = G, C) and ATS. While the *S. thermophilus* Cascade
185 protected ~75% of the library -- indicative of enriched sub-optimal PAMs, the PAM profile matched
186 the few PAM sequences previously confirmed to bind purified Cascade *in vitro* (Sinkunas et al.,
187 2013). Most remaining systems generally recognized AAG as a dominant PAM sequence,
188 although there were notable deviations and additions. For example, one system from *Azotobacter*
189 *chroococcum* NCIMB 8003 (Ac2) principally recognized AA, while another system from
190 *Paracoccus* sp. J4 (Ps) preferentially recognized AAC. Separately, the systems from
191 *Marinomonas* sp. MWYL1 (Ms), and *Ectothiorhodospira halobalkaliphila* ATCC 51935 (Eh) as well
192 as a separate system in *Azotobacter chroococcum* NCIMB 8003 (Ac3) recognized PAM profiles
193 paralleling that recognized by *E. coli*'s system. Notably, Ac2 and Ac3 are present in the same
194 bacterium, suggesting that their partially overlapping PAM profiles could confer redundancy in
195 immune defense as reported for co-occurring Type I and Type III systems (Silas et al., 2017). The
196 distinct PAM profiles that gave measurable activity in the deGFP silencing assay in TXTL
197 confirmed the trends observed with the PAM wheels (**Figs. 3B**). Given that Type I-E systems
198 represent one of the most abundant CRISPR-Cas subtypes in nature (Makarova et al., 2015), our
199 initial characterization suggests that a far greater diversity of recognized PAM profiles likely exists
200 across this expansive subtype.

201
202 **Extensively self-targeting I-C and I-F1 CRISPR-Cas systems in *Xanthomonas albilineans***
203 **are functionally encoded.** Beyond mining individual systems, PAM-DETECT can be further
204 applied to interrogate systems that deviate from traditional immune defense. Prominent examples
205 are self-targeting CRISPR-Cas systems that encode crRNAs targeting chromosomal locations
206 (Wimmer and Beisel, 2019). While self-targeting is considered inherently incompatible with a

207 functional CRISPR-Cas system (Gomaa et al., 2014; Stern et al., 2010; Vercoe et al., 2013),
208 accumulating examples provide important counterpoints where the systems tolerate or even
209 utilize self-targeting crRNAs. For instance, systems encoding self-targeting crRNAs have been
210 associated with prophage-encoded Acrs that actively repress immune defense and serve as
211 markers to uncover novel Acrs (Marino et al., 2018; Rauch et al., 2017; Watters et al., 2018; Yin
212 et al., 2019). Furthermore, a crRNA-like RNA encoded within Type I systems was also shown to
213 direct Cascade to a partially complementary site upstream of a toxin gene, thereby blocking its
214 transcription to ensure maintenance of the CRISPR-Cas system and counter Acr-encoding
215 phages (Li et al., 2021). PAM-DETECT and TXTL therefore could accelerate the characterization
216 of these unique systems.

217 We specifically focused on two extensively self-targeting CRISPR-Cas systems within the
218 plant pathogen *Xanthomonas albilineans* CFBP7063. This bacterium encodes two CRISPR-Cas
219 systems (I-C and I-F1) each harboring the full cohort of *cas* genes and associated with a
220 remarkably large repertoire of self-targeting spacers (**Fig. 4A**). Of the 64 spacers present across
221 the six CRISPR arrays, 24 (38%) at least partially match sites in the chromosome or one plasmid
222 (**Table S4, Fig. S2A**) with a common set of flanking PAMs (**Fig. 4B**). TXTL therefore offered a
223 rapid means to explore the functionality of these systems and why self-targeting is tolerated.

224 We first performed PAM-DETECT using Cascade from both CRISPR-Cas systems (**Fig.**
225 **4C**). Either Cascade protected a small portion of the DNA library (~2% for I-C, ~6% for I-F1) from
226 restriction digestion (**Fig. S2B**), indicating functional expression of all Cascade subunits. PAM-
227 DETECT further revealed PAM profiles that overlapped -- but were not identical to -- the I-C and
228 I-F1 systems with even a moderately mapped PAM profile (Almendros et al., 2012; Leenay et al.,
229 2016; Rao et al., 2017; Rollins et al., 2015; Tuminauskaite et al., 2020; Zheng et al., 2019). In
230 particular, the I-C system from *X. albilineans* recognizes TTC followed by TTT and CTC, while the
231 characterized I-C system from *Bacillus halodurans* recognizes TTC followed by CTC and then
232 TCC (Leenay et al., 2016) and the I-C system from *Legionella pneumophila* recognized TTC

233 followed by TTT and CTT (Rao et al., 2017). Separately, the I-F1 system from *X. albilineans*
234 recognizes CC as the strongest PAM similar to other I-F systems (Almendros et al., 2012; Rollins
235 et al., 2015; Tuminauskaite et al., 2020; Zheng et al., 2019), although *X. albilineans* system also
236 can recognize a G and T but not an A at the -2 position and could tolerate a CC PAM shifted one
237 nucleotide upstream. The recognized PAMs of both I-C and I-F1 systems further overlapped with
238 the PAM sequences flanking the self-targets for 87% of the I-C self-targets (TTC, TTT, CTC) and
239 all I-F1 self-targets (CC, CCT) (**Figs. 4B and C**). Testing these individual PAMs in TXTL using
240 gene repression with Cascade confirmed that the I-C system could recognize not only TTC but
241 also TTT and CTC (**Fig. 4D**). The same TXTL assay confirmed that the I-F1 system could
242 recognize the CC PAM associated with almost all self-targeting. PAM-DETECT therefore can be
243 implemented beyond I-E systems and indicated that the interrogated I-C and I-F1 systems in *X.*
244 *albilineans* are capable of binding the vast majority of self-targeting sites in the genome.

245 If the Cas3 endonuclease for either system is functionally encoded and expressed, then
246 recognition of these self-targeting sites should prove lethal to this bacterium. We therefore
247 reconfigured the TXTL assay to evaluate the extent to which the I-C or I-F1 Cas3 could elicit DNA
248 degradation (**Fig. 4E**). The DNA target was placed in the backbone of the deGFP reporter ~200
249 bps upstream of the deGFP promoter flanked by a TTC (I-C) or CC (I-F1) PAM, which would only
250 lead to loss of deGFP fluorescence if the backbone is nicked or cleaved, leading to DNA
251 degradation by RecBCD (Marshall et al., 2018). For both systems, this new target site location
252 resulted in targeted deGFP silencing following expression of Cascade and Cas3 but not Cascade
253 alone (**Fig. 4E**). Cas3 is therefore functionally encoded and would lead to lethal self-targeting
254 unless Cascade is fully silenced in this bacterium or another mechanism is in place to inhibit
255 Cascade and/or Cas3 activity. The findings thus lay a foundation to investigate the mechanistic
256 basis of self-targeting and whether self-targeting underlies functions extending beyond immune
257 defense.

258

259 **The I-F CRISPR transposon from *Vibrio cholerae* recognizes an extremely flexible PAM**
260 **profile.** The demonstrated applicability of PAM-DETECT for diverse Type I CRISPR-Cas systems
261 created a unique opportunity: applying the same assay to CASTs. Of the three known CAST types
262 (I-B, I-F, V-K), two (I-B, I-F) rely on Cascade for DNA target recognition (Klompe et al., 2019;
263 Saito et al., 2021). Recognition then leads to integration of the transposon DNA at a defined
264 distance downstream of the target. Characterization of these systems to-date has relied on
265 encoding a crRNA, all CRISPR and transposon components, and donor DNA flanked by the
266 transposon ends in bacteria to achieve targeted transposition. However, the reliance of I-B and I-
267 F CASTs on Cascade offers an opportunity to express only these CAST components as part of
268 PAM-DETECT to elucidate key rules for DNA target recognition.

269 We began with the I-F CAST from *V. cholerae* that exhibited robust DNA integration in *E.*
270 *coli* and has been used for multiple applications in bacteria (Klompe et al., 2019; Vo et al., 2021)
271 (**Fig. 5A**). Prior screening of individual potential PAM sequences via transposition in *E. coli*
272 revealed a general preference for a C at the -2 position, although a comprehensive PAM remained
273 to be determined. We therefore applied PAM-DETECT by expressing the three Cascade genes
274 (a natural *cas8-cas5* fusion, *cas6*, and *cas7*) along with the *tniQ* gene responsible for recruiting
275 the other three transposon genes (*tnsA*, *tnsB*, *tnsC*), as the role of TniQ in DNA target recognition
276 remained to be established (Klompe et al., 2019; Petassi et al., 2020; Vo et al., 2021). PAM-
277 DETECT revealed 57% DNA protection under high Cascade conditions (3 nM plasmids, 16 hour
278 reaction time), leading us to also perform PAM-DETECT with the low Cascade conditions (0.25
279 nM plasmids, 6 hour reaction time) that exhibited 25% DNA protection (**Fig. S3A**). We further
280 found that *tniQ* was dispensable for DNA binding (**Fig. S3B**). The resulting PAM profile was
281 remarkably flexible, with a preference for a C and bias against an A at the -2 position (**Figs. 5B,**
282 **S3C**). We further noticed deviations from these biases that could still allow target recognition. For
283 example, recognition of a G or T at the -2 position could be enhanced with a C at the -1 position
284 or an A at the -3 position. Separately, an A at the -2 position could be rescued with a C at the -3

285 position (**Figs. 5B, S3C**). The results from PAM-DETECT therefore suggest that this I-F CAST
286 recognizes a remarkably flexible PAM profile with preferences extending beyond a simple
287 consensus sequence.

288 To evaluate the PAM profile output by PAM-DETECT, we first employed our TXTL-based
289 deGFP silencing assay (**Figs. 5C**). Cascade most strongly recognized PAM sequences with C at
290 the -2 position, with the greatest preference for CC. Deviating from this preference reduced but
291 did not eliminate measurable silencing as long as A was not present at the -2 and -3 positions.
292 Interestingly, while AAA and AAT yielded no measurable deGFP silencing, replacing A with C at
293 the -3 position restored measurable silencing, albeit with low activity (**Fig. 5D**). These small but
294 measurable differences raised the question of how these activities translate into programmable
295 DNA transposition in *E. coli*. We therefore employed the previously described transposition
296 system in which the CAST genes and crRNA are encoded outside of donor DNA flanked by the
297 transposition ends (Klompe et al., 2019), and transposition is conducted at 30°C for higher
298 integration efficiency (Vo et al., 2021). The crRNA is further designed to drive transposition into
299 the *lacZ* gene in the *E. coli* genome, which yields white rather than blue colonies on the cleavable
300 dye X-gal. Using this experimental setup, we found that a CAA but not AAA PAM sequence
301 yielded robust DNA transposition, even though the targets were separated by only one base
302 (**Figs. 5E, S3D and E**). Furthermore, the measured transposition efficiency was similar for CAA
303 and CC. Therefore, even low levels of gene silencing with Cascade in TXTL could yield efficient
304 transposition in *E. coli*.

305

306 **The I-B2 CRISPR transposon from *Rippkaea orientalis* recognizes a less flexible PAM**
307 **profile.** Building on our success applying PAM-DETECT to the I-F CAST from *V. cholerae*, we
308 turned to I-B CASTs. Two examples of I-B CASTs were experimentally characterized very
309 recently, revealing that a second encoded *tniQ* (renamed *tnsD*) drives DNA transposition at
310 conserved sites flanking tRNAs or *glmS* independently of Cascade or a crRNA (Saito et al., 2021).

311 These examples were also previously subjected to a high-throughput PAM determination assay
312 conducted by performing transposition *in vivo* expressing all components in *E. coli*. Type I-B
313 CASTs were further split into two subtypes (I-B1, I-B2) based on the TnsA and TnsB being fused
314 or separate proteins, the general genetic organization of the CAST locus, and crRNA-independent
315 insertion flanking tRNAs or *glmS*.

316 While exploring examples within the I-B CASTs, we noticed a further division within the I-
317 B2 subtype typified by *tnsD* flanking the Cascade genes rather than the other transposon genes
318 (**Fig. 6A**). This organization more closely paralleled that of I-B1 CASTs (Saito et al., 2021) but still
319 possesses the *tnsAB* fusion and the presence of tRNAs flanking the CASTs indicative of I-B2
320 CASTs. The division of the I-B2 CASTs in two clades, denoted hereafter as I-B2.1 and I-B2.2,
321 was further supported by the higher shared similarity of the TnsAB, TnsC, TnsD and TniQ proteins
322 from systems that belong to each clade (**Figs. 6A, S4A**). The Cascade proteins were similar
323 across all I-B CASTs and thus could not help differentiate any divisions within this CAST type
324 (Saito et al., 2021). We chose the I-B2.2 CAST from *Rippkaea orientalis* (RoCAST) as a
325 representative example to characterize.

326 We conducted PAM-DETECT by expressing a single-spacer CRISPR array as well as the
327 four RoCAST Cascade genes (*cas5*, *cas6*, *cas7*, *cas8*) from two separate expression constructs.
328 This combination yielded a PAM profile dominated by ATG (**Figs. 6B, S4B and C**), matching the
329 PAM recognized by the one previously characterized I-B2.1 CAST from *Peltigera membranacea*
330 *cyanobiont* 210A (PmcCAST) (Saito et al., 2021). This match was expected given the high
331 similarity (65-81%) between the protein components forming PmcCAST and RoCAST Cascade.
332 However, single-nucleotide perturbations to ATG could be recognized by the RoCAST even under
333 low Cascade conditions. The TXTL-based deGFP silencing assay confirmed recognition of ATG
334 as well as the single-nucleotide perturbations (**Fig. 6C**). We further showed that PAM-DETECT
335 can be applied to the previously characterized I-B1 CRISPR transposon from *Anabaena variabilis*

336 ATCC 29413 (AvCAST) (Saito et al., 2021) (**Fig. S5A and B**). These insights came from using a
337 streamlined TXTL assay without any protein or RNA purification and only half of the genetic
338 components needed for transposition.

339

340 **DNA transposition by CRISPR transposons can be recapitulated in TXTL.** We next wanted
341 to evaluate how insights into PAM recognition translate into DNA transposition. However, doing
342 so with *in vitro* or cell-based assays posed numerous challenges that would slow the
343 characterization process. In particular, encoding and expressing all of the genetic components
344 into a few compatible plasmids is laborious and could require extensive optimization, while
345 overexpressing some components could be toxic to the cells. Instead, we asked whether
346 transposition could be recapitulated in TXTL (**Fig. 7A**) to rapidly test different configurations and
347 constructs.

348 We began with the *V. cholerae* I-F CAST. Combining DNA constructs encoding a targeting
349 single-spacer array, three Cascade genes, four transposon genes (*tnsA*, *tnsB*, *tnsC*, *tniQ*), donor
350 DNA flanked by the transposon ends, and a target construct resulted in measurable DNA
351 transposition in both orientations by PCR (**Fig. S6A**). Sanger sequencing of the PCR products
352 revealed the core transposon ends as well as the distance between the target site and insertion
353 site that aligned with prior work (**Fig. S6A**). We were also able to reconstitute transposition in
354 TXTL for AvCAST (**Fig. S5C**). Therefore, TXTL can be used to characterize DNA transposition
355 by CASTs.

356

357 **DNA transposition in TXTL with the *Rippkaea orientalis* CAST establishes a distinct branch**
358 **within I-B2 CRISPR transposons.** Building on TXTL-based transposition with the I-F and I-B2.1
359 CASTs, we evaluated DNA transposition in TXTL with the I-B2.2 RoCAST (**Fig. 7B**). Because the
360 ends of this transposon were unclear, we constructed a donor DNA construct flanked by two 250-
361 bp sequences predicted to contain the right and left RoCAST ends. We combined the donor DNA

362 and target DNA flanked by an ATG PAM with constructs encoding the I-B2.2 Cascade genes
363 (*cas5*, *cas6*, *cas7*, *cas8*), transposase genes (*tnsAB*, *tnsC*, *tnsD*, *tniQ*), and a single-spacer
364 CRISPR array with a targeting or non-targeting spacer. The TXTL reactions resulted in
365 measurable crRNA-directed transposition in both orientations by PCR. Sanger sequencing of the
366 PCR products revealed the core transposon ends along with five bases that are duplicated as
367 part of transposition (**Fig. 7B**), similar to other CASTs (Klompe et al., 2019).

368 Recent work revealed that I-B CASTs possess two distinct modes of transposition:
369 CRISPR-dependent transposition through TniQ and DNA targeting by Cascade and CRISPR-
370 independent transposition through TnsD (Saito et al., 2021). We therefore evaluated the role of
371 TniQ and TnsD for either mode of transposition in TXTL. For CRISPR-dependent transposition,
372 TXTL reactions with TniQ yielded the highest CRISPR-dependent transposition efficiency.
373 However, we surprisingly observed modest but detectable crRNA-dependent transposition even
374 in the absence of TniQ and TnsD by PCR (**Fig. 7B and C**) and by next-generation sequencing of
375 the PCR product (**Fig. S6B**). As further support for I-B2.2 as a separate branch, TniQ was
376 reported to be required for crRNA-dependent transposition by the I-B1 AvCAST (**Fig. S5C**) and
377 the I-B2.1 PmcCAST (Saito et al., 2021). To explore CRISPR-independent transposition, we
378 swapped the crRNA target for the tRNA-Leu gene naturally flanking RoCAST in the *R. orientalis*
379 genome. CRISPR-independent transposition was detected in both orientations (**Fig. 7D**).
380 Transposition required TnsAB, TnsC and TnsD, while removing TnsD or replacing it with TniQ
381 eliminated transposition.

382 We finally asked how the properties of RoCAST observed in TXTL translate *in vivo*. We
383 adapted the DNA constructs for use in *E. coli* by condensing the constructs into three plasmids
384 (**Fig. 7E and F**). For CRISPR-dependent transposition, we targeted the *lacZ* gene in the *E. coli*
385 genome at a site flanked by an ATG PAM. Over-expressing Cascade proved to be cytotoxic,
386 reflecting challenges to characterizing CASTs *in vivo*, although the cytotoxicity could be relieved
387 with minimal induction of Cascade expression. In line with the TXTL results, CRISPR-dependent

388 transposition was measurable by PCR in *E. coli* strains expressing the Cascade, TnsAB, TnsC
389 and TniQ proteins, albeit only for the left-to-right insertion orientation (**Fig. 7E**). Removing TnsD
390 boosted this mode of transposition (**Fig. 7E**). Somewhat paralleling the TXTL results, less efficient
391 transposition was measurable by PCR in the absence of TniQ but not both TniQ and TnsD (**Figs.**
392 **7E and S6C**). For CRISPR-independent transposition, we targeted a vector carrying the terminal
393 region of the tRNA-Leu gene from the *R. orientalis* genome. Matching the TXTL results, TnsAB,
394 TnsC, and TnsD proteins were necessary for transposition (**Fig. 7F**). To compare the insertion
395 distances between the target and the inserted donor DNA in TXTL and in *E. coli*, the PCR products
396 were subjected to next-generation sequencing. For CRISPR-dependent transposition,
397 transposition in TXTL consistently occurred 78 bps downstream of the PAM, while transposition
398 in *E. coli* principally occurred within a window of 83-89 bps downstream of the PAM (**Fig. 7G**),
399 although the difference may be attributed to the use of different target sites and insertion contexts
400 as was previously reported for the I-B1 AvCAST (Saito et al., 2021). For CRISPR-independent
401 transposition, transposition in TXTL and in *E. coli* both occurred 31 bps downstream of the tRNA-
402 *Leu* gene (**Fig. 7H**). The insertion distances for both modes of transposition are comparable to
403 the insertion windows identified for the other characterized I-B2 system (Saito et al., 2021).
404 Overall, these findings demonstrate that insights from TXTL-based transposition translate into *in*
405 *vivo* settings.

406

407 **DISCUSSION**

408 Through multiple demonstrations, we showed how cell-free TXTL reactions could be applied to
409 rapidly characterize multi-component CRISPR nucleases as well as CRISPR transposons. One
410 method we used repeatedly, PAM-DETECT, could comprehensively determine PAM sequences
411 recognized by the DNA-binding machinery of an immune system or transposon. Our method
412 offered important advantages over current cell-based and *in vitro*-based methods that should
413 accelerate characterization of Class 1 CRISPR-Cas systems and transposons. PAM-DETECT

414 could be completed in under one day starting from purified DNA constructs and ending with
415 amplicons for next-generation sequencing. In contrast, cell-based methods require DNA
416 transformation, culturing, and growth before DNA isolation that can stretch for days. *In vitro*
417 assays can require even more time due to the need to purify ribonucleoprotein complexes
418 overexpressed in cells. Both traditional methods can require extensive optimization, such as
419 combining the constructs into a small set of compatible plasmids with appropriate expression,
420 tackling issues of toxicity, or troubleshooting issues that arise during purification--steps that are
421 irrelevant for TXTL. Finally, the ability to conduct reactions in a few microliters allows PAM-
422 DETECT to be readily scaled, allowing the parallel interrogation of tens or even hundreds of
423 systems under different reaction conditions. While TXTL reactions are normally conducted
424 between 25°C and 37°C, the DNA-binding and restriction steps could be conducted at elevated
425 temperatures, such as for evaluating CRISPR-Cas systems derived from thermophiles and
426 hyperthermophiles. In addition, while overexpression of Cascade could lead to unwanted
427 enrichment of suboptimal PAMs, we demonstrated how the reaction conditions could be tuned
428 and how qPCR could be applied to gauge the extent of library protection. Given these advantages,
429 TXTL-based characterization of Class 1 systems could represent a widespread means to explore
430 these abundant and diverse systems.

431 We further leveraged TXTL to accelerate the validation and extension of our results from
432 PAM-DETECT. We frequently employed a deGFP repression assay in which target binding by
433 Cascade blocks deGFP expression. This assay allowed us to confirm PAM sequences, where
434 deGFP repression strongly correlated with enrichment with PAM-DETECT for the *E. coli* I-E
435 system. One potential limitation to PAM-DETECT and the repression assay is that binding may
436 not correspond to DNA degradation, as was reported to some degree for DNA binding and
437 degradation by the I-E system (Xue et al., 2015). However, as part of characterizing the self-
438 targeting CRISPR-Cas systems in *X. albilineans*, we showed that the repression assay could be
439 readily modified to specifically assess DNA degradation by Cas3. By targeting a location well

440 upstream of the promoter, a reduction of deGFP expression would only occur through the action
441 of Cas3. This altered setup could be readily applied to validate identified PAMs in the context of
442 DNA degradation. Finally, we showed that DNA transposition by CASTs could be fully
443 recapitulated in TXTL. We were able to recapitulate CRISPR-dependent and CRISPR-
444 independent transposition by I-B and I-F CASTs, suggesting that TXTL would be valid for V-K
445 CASTs representing the third and final subtype (Saito et al., 2021; Strecker et al., 2019). With
446 these additional assays in place, TXTL can be applied well beyond PAM determination.

447 One major application we pursued was mining the natural diversity of I-E CRISPR-Cas
448 systems. Using PAM-DETECT, we evaluated 11 different systems representing diverse
449 sequences within the variable L1 loop of the Cas8e protein. The analysis revealed ranging extents
450 of library protection indicative of Cascade expression, binding activity, and the breadth of
451 recognized PAMs. The identified PAMs deviated from that associated with *E. coli*'s I-E system,
452 suggesting that a far broader range of PAMs could be revealed by further interrogating the
453 diversity of these systems. Whether the diversity parallels that observed for Cas9 nucleases
454 remains to be seen and could reflect the distinct forces that shaped the evolution of each system
455 type (Gasiunas et al., 2020). A similar approach could be particularly powerful for mining I-C and
456 I-Fv Cascade complexes that require the fewest number of Cas proteins (Hochstrasser et al.,
457 2016; Pausch et al., 2017). Complexes could be mined exhibiting not only unique PAM
458 preferences but also smaller proteins, altered temperature ranges, or enhanced binding and
459 cleavage activities. Given the proliferation of engineered single-effectors with altered PAM
460 recognition (Collias and Beisel, 2021), TXTL could be applied to characterize any similarly
461 engineered variants of type I systems.

462 Beyond mining orthologs within a CRISPR-Cas subtype, PAM-DETECT offered a powerful
463 means to interrogate CRISPR-Cas systems with potentially unique properties. We specifically
464 focused on a I-C system and a I-F1 system present in *X. albilineans* that encode a large repertoire
465 of self-targeting spacers. While genetic deactivation of the CRISPR machinery is thought to be a

466 common means of resolving otherwise lethal self-targeting (Stern et al., 2010), we showed that
467 Cascade and Cas3 were functionally encoded and could recognize PAMs flanking the vast
468 majority of the self targets. These findings instead suggest that the expression or activity of the
469 CRISPR machinery is inhibited, preventing lethal self-targeting. One possibility is that the cell
470 encodes Acrs that actively inhibit steps of CRISPR-based immunity or expression (Davidson et
471 al., 2020). Future work therefore could interrogate what is preventing both systems from lethal
472 self-targeting not only in *X. albilineans* but also the many other organisms possessing CRISPR-
473 Cas systems with self-targeting spacers. This work could reveal novel classes of Acrs as well as
474 instances of CRISPR-Cas systems performing functions extending beyond adaptive immunity.

475 As a final example, we applied TXTL to characterize a distinct branch of I-B2 CASTs. The
476 I-B CAST type was recently divided into two subtypes (I-B1 and I-B2) based on whether *tnsA* and
477 *tnsB* were fused, the genetic organization of the CAST, and the site recognized for CRISPR-
478 independent insertion (Saito et al., 2021). When exploring I-B2 CASTs, we noticed a clear division
479 in the genetic organization of these CASTs that paralleled phylogenetic trees for the transposon
480 genes. We further found that CRISPR-dependent transposition could occur in the absence of
481 TniQ for one branch (I-B2.2), contrasting with the essential role of TniQ described for the other
482 branch (I-B2.1) and subtype (I-B1) (Saito et al., 2021). TniQ-independent transposition under
483 these conditions was weak, raising questions whether CRISPR-dependent transposition would
484 occur in the absence of TniQ under natural settings. Regardless of the biological relevance, it
485 likely reflects distinct biomolecular mechanisms and interactions that further support some
486 division in categorization. As only a small number of CASTs have been characterized to-date,
487 further exploring these unique mobile genetic elements could reveal new properties and provide
488 CASTs for further technological development and application. In that regard, applying cell-free
489 systems could greatly aid these efforts and help drive new discoveries and technologies.

490

491 **ACKNOWLEDGEMENTS**

492 We thank Natalia Ivanova for assistance with the bioinformatics identification of Type I-E CRISPR-
493 Cas systems. We thank Sam Sternberg for providing plasmid pSL0283, pSL0284 and pSL0527.
494 This work was supported by an ERC Consolidator grant (865973 to C.L.B.), the Deutsche
495 Forschungsgemeinschaft (BE 6703/1-1 to C.L.B.), and the Netherlands Organization for Scientific
496 Research (NWO) through a Rubicon Grant (project 019.193EN.032 to I.M.). A portion of this
497 research was performed under the JGI-EMSL Collaborative Science Initiative and used resources
498 at the DOE Joint Genome Institute and the Environmental Molecular Science Laboratory, which
499 are DOE Office of Science User Facilities. Both facilities are sponsored by the Office of Biological
500 and Environmental Research and operated under Contract Nos. DE-AC02-05CH11231 (JGI) and
501 DE-AC05-76RL01830 (EMSL).

502

503 **AUTHOR CONTRIBUTIONS**

504 Conceptualization: F.W., I.M., C.L.B.; Methodology: F.W., I.M., C.L.B., Software: F.W., I.M.,
505 Validation: F.W., I.M., F.E.; Investigation: F.W., I.M., F.E., Writing - Original Draft: F.W., I.M.,
506 C.L.B., Writing - Review & Editing: F.W., I.M., F.E., C.L.B. Visualization: F.W., I.M., C.L.B.,
507 Supervision: C.L.B.; Funding acquisition: C.L.B.


508

509 **DECLARATION OF INTERESTS**

510 C.L.B. is a co-founder and member of the Scientific Advisory Board member for Locus
511 Biosciences and is a member of the Scientific Advisory Board for Benson Hill. The other authors
512 declare no competing interests.

513 **FIGURE TITLES AND LEGENDS**

514



516 **Figure 1.** PAM-DETECT, a TXTL-based PAM determination assay for multi-protein CRISPR
517 effectors.

518 (A) DNA components added to a TXTL reaction to perform PAM-DETECT. The Cascade genes
519 can be encoded on separate plasmids as shown here or as an operon.

520 (B) Steps comprising PAM-DETECT. RE: restriction enzyme.

521 (C) Determination of library protection from restriction cleavage by qPCR. A reaction conducted
522 without the Cascade and crRNA plasmids serves as a negative control.

523 (D) Determination of PAM enrichment by Sanger sequencing.

533 library generation, as TCAAG represented the most prevalent sequence in the library. As a result,
534 protection of an AAG motive protects the majority of the TCAAG sequences.


535 **(D)** Nucleotide-enrichment plots and PAM wheels based on conducting PAM-DETECT with low
536 or high levels of Cascade. Individual sequences comprising at least 2% of the PAM wheel are
537 shown. Results represent the average of duplicate independent experiments. The size of the arc
538 for an individual sequence corresponds to its relative enrichment within the library.

539 **(E)** Overview of the TXTL-based PAM validation assay. PAM sequences are tested by Cascade
540 binding target R flanked by the tested PAM. Because target R overlaps the promoter driving
541 expression of deGFP, target binding would block deGFP expression. Target R is distinct from the
542 restriction site-containing target used with PAM-DETECT.

543 **(F)** Correlation between PAM enrichment from PAM-DETECT and gene repression in TXTL.
544 Enrichment was based on the fraction of the PAM wheel derived from the low Cascade condition.
545 Enrichment values represent the mean of duplicate PAM-DETECT assays, while fold-reduction
546 values represent the mean of triplicate TXTL assays. Fold-reduction was calculated based on a
547 non-targeting crRNA control.

548 **(G)** TXTL validation of PAM sequences identified by PAM-DETECT but not by PAM-SCANR.
549 CAAAG serves as a positive control. AACCG matches the 3' end of the repeat and therefore
550 serves as a negative control. The AACCG self PAM is the reference for statistical analyses.

551 Error bars in B and G indicate the mean and standard deviation of triplicate independent
552 experiments. ***: $p < 0.001$. **: $p < 0.01$. *: $p < 0.05$. ns: $p > 0.05$.




554 **Figure 3.** Harnessing the functional diversity of I-E CRISPR-Cas systems.

555 **(A)** Nucleotide enrichment plots and PAM wheels for selected I-E systems subjected to PAM-
 556 DETECT. See Figure S1 for 5 additional systems subjected to PAM-DETECT. Ac1 (in Figure S1),
 557 Ac2, and Ac3 are present in the same bacterium. Individual Ms sequences comprising at least 2% of
 558 the PAM wheel are shown. Plots and PAM wheels are averages of duplicate independent
 559 experiments.

560 **(B)** Comparison of PAM recognition between systems. Recognition was determined by assessing
 561 repression of a deGFP reporter in TXTL. Values represent the mean of three TXTL experiments.

562 Fold-reduction values that are not significantly different from that of the non-targeting crRNA
563 control ($p > 0.05$) are shown as white squares. The PAM sequence showing the highest fold-
564 reduction for each system was set to 100%. AACCG matches the 3' end of the repeat for most of
565 the systems.



567 **Figure 4.** Interrogating extensive self-targeting for two type I CRISPR-Cas systems in
 568 *Xanthomonas albilineans*.

569 **(A)** Overview of the I-C and I-F1 CRISPR-Cas systems and self-targeting spacers. The genes
570 encoding the Cascade complex are in the light blue box (I-C) or the light orange box (I-F1), while
571 the genes encoding the acquisition proteins are in the gray box.


572 **(B)** Distribution of PAMs associated with the self-targets. See Figure S2 for the self-target
573 location and Table S4 for the self-target sequences.

574 **(C)** Nucleotide-enrichment plots and PAM wheels based on conducting PAM-DETECT. Individual
575 sequences comprising at least 2% of the PAM wheel are shown. Plots and PAM wheels are
576 averages of duplicate independent experiments.

577 **(D)** Validation of PAMs associated with self-targets in TXTL. Fold-reduction was calculated based
578 on a non-targeting crRNA control. GAAAC and AGAAA match the 3' end of the repeat for the I-C
579 and I-F1 systems, respectively. Either self PAM is the reference for statistical analyses.

580 **(E)** Assessing DNA binding by Cascade and DNA degradation by Cas3 in TXTL. Targeting far
581 upstream of the promoter (target D) can reduce deGFP levels only through degradation of the
582 plasmid. Targeting the promoter (target R) can reduce deGFP levels through DNA binding or
583 plasmid degradation. Fold-reduction was calculated based on a non-targeting crRNA control. The
584 non-targeting crRNA control is the reference for statistical analyses. Target D with only the I-F1
585 Cascade yielded modestly but significantly altered deGFP levels between targeting and non-
586 targeting conditions, although targeting resulted in an increase in deGFP levels.

587 Errors bars in D and E indicate the mean and standard deviation of triplicate independent
588 experiments. ***: $p < 0.001$. **: $p < 0.01$. *: $p < 0.05$. ns: $p > 0.05$.



590 **Figure 5.** Interrogating the PAM profile of the *Vibrio cholerae* I-F CRISPR transposon.

591 **(A)** Overview of *V. cholerae* I-F CRISPR transposon and its mechanism of transposition.

592 **(B)** Nucleotide-enrichment plot and PAM wheel based on conducting PAM-DETECT with
 593 Cascade and TniQ. Individual sequences comprising at least 1% of the PAM wheel are shown.
 594 The plot and PAM wheel are averages of duplicate independent experiments.

595 **(C)** Validation of PAMs in TXTL. Gene repression was evaluated with Cascade and the indicated
 596 PAM flanking target R upstream of the deGFP reporter. See Figure 2E for details. Fold-reduction
 597 was calculated based on a non-targeting crRNA control. ATAAC matches the 3' end of the repeat
 598 and therefore serves as a negative control. The ATAAC self PAM is the reference for statistical
 599 analyses.

600 **(D)** Individual measurements of endpoint deGFP levels in TXTL. Triplicate values are shown for
 601 selected PAMs with a targeting (T) or non-targeting (NT) crRNA. See C for details.


602 (E) Validation of PAM recognition for DNA transposition in *E. coli*. Donor DNA is inserted within
603 the *lacZ* gene, preventing the formation of blue colonies on IPTG and X-gal. Different targets
604 within *lacZ* were selected to test the indicated PAM. The targets for the CAA and AAA PAMs are
605 shifted by one nucleotide. See Figure S3 for more information.
606 Error bars in C, D, and E indicate the mean and standard deviation of triplicate independent
607 experiments. ***: $p < 0.001$. **: $p < 0.01$. *: $p < 0.05$. ns: $p > 0.05$.

616 **(B)** Nucleotide-enrichment plot and PAM wheel based on conducting PAM-DETECT with
617 Cascade from RoCAST. Individual sequences comprising at least 2% of the PAM wheel are
618 shown. The plot and PAM wheel are averages of duplicate independent experiments.

619 **(C)** Validation of PAMs in TXTL. Gene repression was evaluated with Cascade and the indicated
620 PAM flanking target R upstream of the deGFP reporter. See Figure 2E for details. Fold-reduction
621 was calculated based on a non-targeting crRNA control. CTCAA matches the 3' end of the repeat
622 and therefore serves as a negative control. The CTCAA self PAM is the reference for statistical
623 analyses.

624 Error bars in C indicate the mean and standard deviation of triplicate independent experiments.

625 ***: $p < 0.001$. **: $p < 0.01$. *: $p < 0.05$. ns: $p > 0.05$.



627 **Figure 7.** Investigating transposition of the *Rippkaea orientalis* I-B2.2 CRISPR transposon in
 628 TXTL and in *E. coli*.

629 **(A)** Overview of the TXTL-based transposition assay. For I-B CRISPR transposons, transposition
630 can occur through crRNA-guided recognition of a DNA target or through TnsD-guided recognition
631 of *glmS* or a tRNA gene independent of the CRISPR machinery. Primers (red) are shown to
632 selectively amplify the transposition product. The *R. orientalis* I-B2.2 CRISPR transposon
633 (RoCAST) flanks the tRNA-Leu gene.

634 **(B)** CRISPR-dependent transposition and determination of transposon ends and insertion
635 distance using the TXTL-based transposition assay with RoCAST. PCR products are specific to
636 the left-right orientation and span the crRNA target site and the beginning of the cargo (left TE)
637 or the end of the cargo and downstream of the insertion site (right TE).

638 **(C)** CRISPR-dependent transposition in TXTL. PCR products span the crRNA target site and the
639 beginning of the cargo for both orientations of transposon insertion.

640 **(D)** CRISPR-independent transposition in TXTL. PCR products span the end of the tRNA-Leu
641 gene and the beginning of the cargo for both orientations of transposon insertion.

642 **(E)** CRISPR-dependent transposition in *E. coli*. PCR products span the crRNA target site and the
643 beginning of the cargo (left-right orientation).

644 **(F)** CRISPR-independent transposition in *E. coli*. PCR products span the TnsD target site and the
645 beginning of the cargo (left-right orientation).

646 **(G)** Assessment of insertion distances for CRISPR-dependent transposition in TXTL and in *E.*
647 *coli*. The constructs lacking *tnsD* were used. Transposition was determined by next-generation
648 sequencing of the PCR product spanning the crRNA target site and the beginning of the cargo
649 (left-right orientation).

650 **(H)** Assessment of insertion distances for CRISPR-independent transposition in TXTL and in *E.*
651 *coli*. The constructs lacking *tniQ* were used. Transposition was determined by next-generation
652 sequencing of the PCR product spanning the end of the tRNA-Leu gene and the beginning of the
653 cargo (left-right orientation).

654 All gel images are representative of at least duplicate independent experiments.

655 **STAR METHODS**

656

657 **METHOD DETAILS**

658 **Plasmid construction**

659 Standard cloning methods Gibson Assembly, Site Directed Mutagenesis (SDM) and Golden Gate
660 were used to clone plasmids used in TXTL experiments. pPAM_library containing a PAM library
661 with five randomized nucleotides was generated by SDM on p70a-deGFP_Pacl with primers
662 FW531 and FW532 (**Table S5**). Single-spacer CRISPR arrays were generated either with Golden
663 Gate adding spacer sequences in a plasmid containing two repeat sequences interspaced by two
664 BaeI or BbsI restriction sites or by SDM on pEc_gRNA1, pEc_gRNA2 or pEc_gRNAnt to change
665 the repeat sequences to match the tested CRISPR systems. Plasmids harboring different PAM
666 sequences for PAM validation assays were generated by SDM on p70a-deGFP_Pacl. To
667 generate plasmids encoding *X. albilineans* type I-C and type I-F1 Cas proteins, genomic DNA
668 isolated from *Xanthomonas albilineans* CFBP7063 was PCR amplified using Q5 Hot Start High-
669 Fidelity 2X Master Mix (NEB) and cloned into pET28a using Gibson Assembly. All other plasmids
670 were generated with Gibson Assembly or SDM (**Table S5**). All constructed plasmids were verified
671 with Sanger sequencing.

672

673 For the VcCAST *in vivo* transposition experiments we cloned into the previously described
674 pSL0284 vector (Klompe et al., 2019) two spacers targeting the *lacZ* gene of the *E. coli* BL21
675 (DE3) genome, yielding the pQCas_CAA and pQCas_AAA vectors. The protospacer targeted by
676 the former vector has a 5'CAA PAM, whereas the protospacer targeted by the latter vector has a
677 5'AAA PAM.

678

679 For the RoCAST *in vivo* transposition experiments, genes encoding the *Rippkaea orientalis*
680 *tnsAB*, *tnsC*, *tnsD* and *tniQ* were synthesized (Twist Bioscience) and cloned in the pET24a vector

681 in various combinations, resulting in the construction of the pRoTnsABC, pRoTnsABCD,
682 pRoTnsABCQ, pRoTnsABCDQ vectors (**Table S5**). The *Rippkaea orientalis* Cascade operon
683 (*cas6*, *cas8*, *cas7*, *cas5*) was synthesized (Twist Bioscience) and cloned into the pCDFDuet-1
684 vector together with a *gfp* gene flanked by two BsaI restriction sites and the corresponding
685 CRISPR direct repeats. Into the resulting pRoCascade_*gfp* vector we cloned a spacer targeting
686 the *lacZ* gene of the *E. coli* BL21 (DE3) genome and a non-targeting control spacer, constructing
687 the pRoCascade_T (targeting) and pRoCascade_NT (non-targeting) vectors, respectively (**Table**
688 **S5**). DNA fragments encoding the right and left RoCAST ends were synthesized (IDT) and cloned
689 into the pUC19 vector flanking a *gfp* gene, yielding pRoDonor (**Table S5**). A 105-bp long DNA
690 fragment from the *Rippkaea orientalis* genome, encoding the region which is located right
691 upstream of the left end of RoCAST and includes the last 74 bp of the *tRNA-Leu* gene, was
692 synthesized (IDT) and cloned into the pCDFDuet-1 vector, resulting in the construction of the
693 pRoTarget vector (**Table S5**).

694

695 **PAM-DETECT**

696 A plasmid with five randomized nucleotides flanking a target site covering a PaeI restriction
697 enzyme recognition site was constructed as described before. If Cas proteins required for
698 Cascade formation were encoded on separate plasmids, a MasterMix with the required Cas
699 protein encoding plasmids in their stoichiometric amount was prepared beforehand. Thereby, a
700 stoichiometry of Cas8_{e1}-Cse2₂-Cas7₆-Cas5₁-Cas6₁ was used for all Type I-E systems. A 6 μ L
701 TXTL reaction was assembled consisting of 3 nM (high Cascade) or 0.25 nM (low Cascade) of
702 the Cascade-encoding plasmid or the Cascade MasterMix, 4.5 μ L myTXTL Sigma 70 Master Mix,
703 0.2 nM pET28a_T7RNAP, 0.5 mM IPTG, 1 nM gRNA-encoding plasmid and 1 nM pPAM_library.
704 A negative control containing all components from the reaction besides the Cascade plasmids
705 and the gRNA-expressing plasmid was included. PAM-DETECT assays assessing either the type
706 I-C or the type I-F1 system in *X. albilineans* were lacking IPTG in their reactions. TXTL reactions

707 were incubated at 29°C for 6 h or 16 h. The samples were diluted 1:400 in nuclease-free H₂O.
708 500 µL were digested at 37°C with PaeI (NEB) at 0.09 units/µL in 1x CutSmart Buffer (NEB) for 1
709 h and 500 µL were used as a “non-digested” control by adding nuclease-free H₂O instead of PaeI.
710 After inactivation of PaeI at 65°C for 20 min, 0.05 mg/mL Proteinase K (GE Healthcare) was added
711 and incubated at 45°C for 1 h. After inactivation of Proteinase K at 95 °C for 5 min, remaining
712 plasmids were extracted via standard EtOH precipitation. Illumina adapters with unique dual
713 indices were added by two amplification steps with KAPA HiFi HotStart Library Amplification Kit
714 (KAPA Biosystems) and purified by Agencourt AMPure XP (Beckman Coulter) after every PCR
715 reaction. The first PCR reaction adds the Illumina sequencing primers with primers that can be
716 found in Table S5 using 15 µL of the EtOH-purified samples in a 50 µL reaction and 19 cycles.
717 The second PCR adds the unique dual indices and the flow cell binding sequence using 1 ng
718 purified amplicons generated with the first PCR using 18 cycles. The samples were submitted for
719 next-generation sequencing with 50 bp paired-end reads with 1.25 or 2.0 million reads per sample
720 on an Illumina NovaSeq 6000 sequencer. PAM wheels were generated according to Leenay et
721 al. (Leenay et al., 2016). Nucleotide enrichment plot generation was adapted to the script from
722 Marshall et al. (Marshall et al., 2018) by changing the script to visualize the probability of a given
723 nucleotide at a given position by depicting the percentage of the nucleotide in that position. All
724 PAM-DETECT assays were done in duplicates and PAM wheel and nucleotide enrichment plots
725 show averages. The generated NGS data have been deposited in NCBI's Gene Expression
726 Omnibus (Edgar et al., 2002) and are accessible through GEO Series accession number
727 GSE179614 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE179614>). The following
728 token can be used to access the data prior to publication: exexiqgyhrclbj.

729

730 **qPCR Reactions**

731 To assess the remaining amount of PAM-library containing plasmid after conducting PAM-
732 DETECT, quantitative PCR (qPCR) was performed using SsoAdvanced Universal SYBR Green

733 Supermix (Biorad) in 10 μ L reactions. The reactions were quantified using a QuantStudio Real-
734 Time PCR System (Thermo Fisher) with an annealing temperature of 68 $^{\circ}$ C according to
735 manufacturers' instructions. All samples were prepared by using the liquid handling machine
736 Echo525 (Beckman Coulter).

737

738 **deGFP repression assays in TXTL**

739 To assess activity of CRISPR-Cas systems, deGFP-repression assays in 3 μ L or 5 μ L TXTL
740 reactions were conducted, measuring deGFP-expression over time in a 96-well V-bottom plate
741 with BioTek Synergy H1 plate reader (BioTek) at 485/528 nm excitation/emission (Shin and
742 Noireaux, 2012). All TXTL samples were either prepared by hand or by using the liquid handling
743 machine Echo525 (Beckman Coulter).

744

745 3 μ L TXTL reactions for PAM validation assays were prepared containing Cascade plasmid
746 concentrations according to Table S2. If Cas proteins required for Cascade formation were
747 encoded on separate plasmids, a MasterMix with the required Cas protein encoding plasmids in
748 their stoichiometric amount was prepared beforehand. Thereby, a stoichiometry of Cas5₁-Cas8₁-
749 Cas7₇ was used for *X. albilineans* Type I-C, Cas8f1₁-Cas5f1₁-Cas7f1₆-Cas6f₁ was used for *X.*
750 *albilineans* Type I-F1 and Cas8e₁-Cse2₂-Cas7₆-Cas5₁-Cas6₁ was used for all Type I-E systems.
751 Other components included in the TXTL reactions were 2.25 μ L myTXTL Sigma 70 Master Mix,
752 0.2 nM p70a_T7RNAP, 0.5 mM IPTG and 1 nM gRNA-encoding plasmid. After a 4 h pre-
753 incubation at 29 $^{\circ}$ C or 37 $^{\circ}$ C that allowed the ribonucleoprotein complex of Cascade and crRNA
754 to form, 1 nM reporter plasmid (pGFP_XXXXX) with various PAM sequences in close proximity
755 to the promoter driving deGFP expression was added to the reaction to ensure Cascade-binding
756 would lead to deGFP inhibition. The reactions were incubated for additional 16 h at 29 $^{\circ}$ C or 37
757 $^{\circ}$ C while measuring deGFP expression. The gRNAs were constructed to target a protospacer
758 within the *degfp* promoter located adjacent to the various PAM sequences.

759

760 To test the cleavage and/or binding ability of the type I-C and the type I-F1 systems in *X.*
761 *albilineans*, 3 μ L TXTL assays were conducted containing Cascade-encoding plasmids in the
762 stoichiometry as mentioned before. To test binding ability, 2.25 μ L myTXTL Sigma 70 Master Mix,
763 0.2 nM p70a_T7RNAP, 0.5 mM IPTG, 1 nM gRNA1-, gRNA2, or gRNAnt-encoding plasmid and
764 1 nM or 0.25 nM Cascade MasterMix was added to a TXTL reaction for the type I-C and type I-
765 F1 system, respectively. To test cleavage ability, 2.25 μ L myTXTL Sigma 70 Master Mix, 0.2 nM
766 p70a_T7RNAP, 0.5 mM IPTG, 1 nM gRNA1-, gRNA2, or gRNAnt-encoding plasmid, 1 nM
767 Cascade MasterMix and 0.5 nM or 0.25 nM pXalb_IC_Cas3 or pXalb_IF_Cas2-3 was added to a
768 TXTL reaction for the type I-C and type I-F1 system, respectively. After 4 h pre-expression at
769 29°C, 1 nM p70a_deGFP reporter plasmid was added to the reactions and incubated for
770 additional 16 h at 29°C while measuring deGFP-fluorescence. gRNA1 is designed to target a
771 protospacer within the promoter driving deGFP expression adjacent to a type I-C TTC or a type
772 I-F1 CC PAM to ensure Cascade-binding would lead to deGFP-inhibition. gRNA2 is designed to
773 target a protospacer adjacent to a type I-C TTC or a type I-F1 CC PAM upstream of the promoter
774 to ensure cleavage of the targeted plasmid would result in deGFP-inhibition whereas binding-only
775 would result in deGFP-production. gRNAnt represents a non-targeting control.

776

777 5 μ L TXTL reactions assessing dispensability of TniQ for *V. cholerae* I-F CAST Cascade-binding
778 were performed with reactions containing 3.75 μ L myTXTL Sigma 70 Master Mix, 0.2 nM
779 p70a_T7RNAP, 0.5 mM IPTG and 0.5 nM pVch_IF_CasQ_gRNA3/nt or 0.5 nM
780 pVch_IF_Cas_gRNA3/nt. After a 4 h pre-incubation step at 29 °C, the reporter plasmid
781 p70a_deGFP was added and the reactions were incubated for additional 16 h at 29 °C while
782 measuring deGFP-fluorescence. gRNA3 is designed to target a protospacer within the promoter
783 driving deGFP expression adjacent to a CC PAM. gRNAnt represents a non-targeting control.

784

785 **Transposition in TXTL**

786 To assess crRNA-dependent transposition of the *Vibrio cholerae* Tn6677 I-F CAST in TXTL, 5 μ L
787 TXTL reactions containing 3.75 μ L myTXTL Sigma 70 Master Mix, 0.2 nM p70a_T7RNAP, 0.5
788 mM IPTG, 1 nM of the previously described donor plasmid (pSL0527), 2 nM of the previously
789 described TnsABC-plasmid (pSL0283) (Klompe et al., 2019), 1 nM p70a_deGFP and 1 nM
790 pVch_IF_CasQ_gRNA3 or pVch_IF_CasQ_gRNAnt were prepared. The reactions were
791 incubated at 29 °C for 16 h. Transposition events were detected in a 1:400 dilution of the TXTL
792 reaction by PCR amplification using Q5 Hot Start High-Fidelity 2X Master Mix (NEB) and
793 combinations of donor DNA and genome specific primers. Transposition was verified by Sanger
794 sequencing (**Table S5**).

795

796 crRNA-dependent transposition of RoCAST in TXTL was performed in 3 μ L TXTL reactions
797 consisting of 2.25 μ L myTXTL Sigma 70 Master Mix, 0.2 nM p70a_T7RNAP, 0.5 mM IPTG, 1 nM
798 pRoCascade, 1 nM pRo_gRNA2/nt, 1 nM pGFP_CAATG, 1 nM pRoDonor or
799 pRoDonor_extended and 1 nM pRoTnsABC, pRoTnsABCD, pRoTnsABCQ or pRoTnsABCDQ.
800 The reactions were incubated at 29 °C for 16 h. Transposition events were detected in a 1:100
801 dilution of the TXTL reaction by PCR amplification using Q5 Hot Start High-Fidelity 2X Master Mix
802 (NEB) and combinations of donor DNA and genome specific primers (**Table S5**). Transposition
803 was verified by Sanger sequencing.

804

805 crRNA-independent transposition of RoCAST in TXTL was performed in 3 μ L TXTL reactions
806 consisting of 2.25 μ L myTXTL Sigma 70 Master Mix, 0.2 nM p70a_T7RNAP, 0.5 mM IPTG, 1 nM
807 pRoTarget, 1 nM pRoDonor and 1 nM pRoTnsABC, pRoTnsABCD, pRoTnsABCQ or
808 pRoTnsABCDQ. The reactions were incubated at 29 °C for 16 h. Transposition events were
809 detected in a 1:100 dilution of the TXTL reaction by PCR amplification using Q5 Hot Start High-

810 Fidelity 2X Master Mix (NEB) and combinations of donor DNA and genome specific primers
811 (**Table S5**). Transposition was verified by Sanger sequencing.

812

813 **Transposition *in vivo***

814 For the crRNA-dependent transposition *in vivo* using the I-F CAST from *Vibrio cholerae* Tn6677,
815 we employed the previously described transposition system (Klompe et al., 2019). We
816 electroporated 30 ng of the pSL0283 vector with 30 ng of the pSL0527 vector and 30 ng of either
817 the pQCas_CAA or pQCas_AAA vector into *E. coli* BL21(DE3) electrocompetent cells. We plated
818 a fraction of each electroporation mixture on 100 mg/ml ampicillin, 50 mg/ml spectinomycin, 50
819 mg/ml kanamycin, 0.1 mM IPTG and 100 µg/ml X-gal containing LB-agar plates. The plates were
820 incubated for 24 h at 30°C and the formed colonies were subjected to blue/white screening.
821 Transposition events were identified by colony PCR using Q5 Hot Start High-Fidelity 2X Master
822 Mix (NEB) and genome specific primers (**Table S5**).

823

824 For the crRNA-dependent transposition *in vivo* using RoCAST, we electroporated 30 ng of either
825 pRoCascade_T or pRoCascade_NT vector with 30 ng of pRoDonor and 30 ng of either
826 pRoTnsABC, pRoTnsABCD, pRoTnsABCQ or pRoTnsABCDQ vector into *E. coli* BL21(DE3)
827 electrocompetent cells. We plated a fraction of each electroporation mixture on 100 mg/ml
828 ampicillin, 50 mg/ml spectinomycin, and 50 mg/ml kanamycin containing LB-agar plates. The
829 plates were incubated for 20 h at 37°C and the formed colonies were scraped and resuspended
830 in LB liquid medium. A fraction of each cell suspension was re-plated on LB-agar plates
831 supplemented with 100 mg/ml ampicillin, 50 mg/ml spectinomycin, 50 mg/ml kanamycin and 0.01
832 mM IPTG for induction of the expression of the Cascade and transposase proteins. The plates
833 were incubated 20 h at 37°C and all the formed colonies were scraped and resuspended in LB
834 liquid medium. A fraction of each cell suspension was subjected to gDNA isolation using the
835 illustra Bacteria genomicPrep Mini Spin Kit (GE Healthcare). Transposition events were identified

836 by PCR using Q5 Hot Start High-Fidelity 2X Master Mix (NEB) and combinations of donor DNA
837 and genome specific primers (**Table S5**).

838

839 For the crRNA-independent *in vivo* transposition using RoCAST, we electroporated 30 ng of the
840 pRoTarget with 30 ng of pRoDonor and 30 ng of either the pRoTnsABC, pRoTnsABCD,
841 pRoTnsABCQ or pRoTnsABCDQ vector into *E. coli* BL21(DE3) electrocompetent cells. We plated
842 a fraction of each electroporation mixture on 100 mg/ml ampicillin, 50 mg/ml spectinomycin, and
843 50 mg/ml kanamycin containing LB-agar plates. The plates were incubated for 20 h at 37°C and
844 the formed colonies were scraped and resuspended in LB liquid medium. A fraction of each cell
845 suspension was re-plated on LB-agar plates supplemented with 100 mg/ml ampicillin, 50 mg/ml
846 spectinomycin, 50 mg/ml kanamycin and 0.01 mM IPTG for induction of the expression of the
847 transposase proteins . The plates were incubated 20 h at 37°C and all the formed colonies were
848 scraped and resuspended in LB liquid medium. A fraction of each cell suspension was subjected
849 to gDNA isolation using the illustra Bacteria genomicPrep Mini Spin Kit (GE Healthcare).
850 Transposition events were identified by PCR using Q5 Hot Start High-Fidelity 2X Master Mix
851 (NEB) and combinations of donor DNA and pRoTarget specific primers (**Table S5**).

852

853 **Assessing transposition insertion point**

854 To assess the exact insertion point of *Rippkaea orientalis* I-B2.2 CAST, *in vivo* and *in vitro*,
855 transposition assays were conducted as previously described and the transposition products were
856 PCR amplified and sent for next-generation sequencing. Illumina adapters with unique dual
857 indices were added by two amplification steps with KAPA HiFi HotStart Library Amplification Kit
858 (KAPA Biosystems) and each amplicon was purified by Agencourt AMPure XP (Beckman
859 Coulter). The first PCR reaction adds the Illumina sequencing primer sites with primers that can
860 be found in Table S5, the second PCR adds the unique dual indices and the flow cell binding
861 sequences. 2 µL of 1:100 dilutions were used in a 50 µL PCR reaction to amplify TXTL reactions

862 using either 19 or 30 cycles. 50 ng of genomic DNA were used in a 50 μ L PCR reaction to amplify
863 *in vivo* transposition with either 19 or 30 cycles. 1 ng of purified TXTL or *in vivo*-amplicon were
864 subjected to the second PCR using 18 cycles. Library-pools consisting of six samples were
865 submitted for next-generation sequencing with 300 paired-end reads with 0.15 million reads on
866 an Illumina MiSeq machine.

867
868 The generated NGS data have been deposited in NCBI's Gene Expression Omnibus (Edgar et
869 al., 2002) and are accessible through GEO Series accession number GSE179614
870 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE179614>). The following token can be
871 used to access the data prior to publication: exexiqgyhrclbj.

872

873 **QUANTIFICATION AND STATISTICAL ANALYSIS**

874 **deGFP repression assays in TXTL**

875 The fluorescence background was subtracted from the endpoint deGFP values with TXTL
876 samples consisting of only myTXTL Sigma 70 Master Mix and nuclease-free water. The resulting
877 endpoint deGFP values were either depicted as averages of a targeting gRNA and a non-targeting
878 gRNA or fold change-repression was calculated by the ratio of non-targeting over the targeting
879 deGFP values. Significance was calculated with Welch's t-test. $P > 0.05$ is shown as ns, $P < 0.05$
880 is shown as *, $P < 0.01$ is shown as ** and $P < 0.001$ is shown as ***. Within the PAM validation
881 assays represented as fold changes, significance was calculated between the fold change of a
882 given PAM and the fold change of a PAM that corresponds to the 3' end of the repeat of the tested
883 CRISPR system. The fold changes of the PAM validation in Fig. 3B are depicted in a heat map.
884 Thereby a difference between a non-targeting sample and a targeting sample with a specific PAM
885 resulting in $P > 0.05$ is shown in white and excluded from further analysis. For all other samples
886 within the heat map, the fold changes were calculated as mentioned above and presented relative
887 to the highest fold change within one system. Significance within the deGFP repression assays

888 testing binding and cleavage ability of the type I-C and the type I-F1 system in *X. albilineans* was
889 calculated with the targeting and non-targeting sample for each condition. For the endpoint
890 measurements in Fig. 5C, significance was calculated between a non-targeting sample and a
891 targeting sample targeting the same PAM.

892

893 **qPCR**

894 Cq values were used to measure target amounts. To calculate the relative abundance of the PAM
895 library containing plasmid in the digested sample to the non-digested sample, the relative plasmid
896 amount was normalized to a control amplifying the pET28a-T7RNAP that has no PacI recognition
897 site using the the $2^{-(ddCt)}$ method. Significance to the control sample lacking a CRISPR-Cas
898 system was calculated with Welch's t-test. $P > 0.05$ is shown as ns, $P < 0.05$ is shown as *, $P <$
899 0.01 is shown as ** and $P < 0.001$ is shown as *** .

900

901 **Assessing transposition insertion point**

902 ~15 nts long sequences 5' of the transposon terminal left end were extracted, counted and sorted.
903 The sequences were mapped to the targeted plasmid or the targeted genome tolerating 2 nts
904 mismatches and the distance between the insertion point and the PAM upstream of the
905 protospacer or the end of the *tRNA-Leu* gene was noted. To only depict reliable insertion points,
906 we present insertion points with more than 20 reads. The insertion points are shown as bar
907 graphs.

908

909 The processed NGS data have been deposited in NCBI's Gene Expression Omnibus (Edgar et
910 al., 2002) and are accessible through GEO Series accession number GSE179614
911 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE179614>). The following token can be
912 used to access the data prior to publication: exexiqgyhrclbj.

913

914 ***In silico* selection of representative type I-E CRISPR-Cas systems for PAM-DETECT**

915 HMM profiles for the Cas5e, Cas6e, Cas7e and Cas8e proteins were developed upon aligning
916 the members of the corresponding protein families (Cas5e: pfam09704, TIGR1868, TIGR02593;
917 Cas6e: pfam08798, TIGR01907; Cas7e: pfam09344, TIGR01869; Cas8e: pfam 09481,
918 TIGR02547). A new HMM profile was generated for the less conserved Cse2 protein upon
919 aligning sequences with known 3D structure using PROMALS3D server (Pei et al., 2008) followed
920 by a series of iterative alignment/model building steps to include additional sequences and
921 increase sequence diversity. For the aligning processes of all five proteins, sequences were
922 dereplicated at 90% identity using cd-hit (Huang et al., 2010) (with options -c 0.90 -g 1 -aS 0.9).
923 The dereplicated sequences were compared against each other using blastp from blast+ v2.6.0
924 (Altschul et al., 1990) with e-value 10e-05 and defaults for the rest of parameters. Hits were filtered
925 to retain those at >=60% pairwise identity, and were next clustered using the mcl algorithm
926 (Enright et al., 2002) with inflation parameter of 2.0. Clusters with >=10 members were aligned
927 using Gismo (Neuwald and Liu, 2004) with default parameters, and consensus sequences were
928 extracted from the alignments. These consensus sequences, as well as singletons and
929 sequences from smaller clusters were aligned using Gismo (Neuwald and Liu, 2004). Alignments
930 were manually curated to remove shorter sequences that did not have one or more of the active
931 site positions and HMM profiles were generated using hmmbuild (Eddy, 2009). Hmmssearch
932 (Eddy, 2009) using the generated HMM profiles against all public genomes (isolates, SAGs, and
933 MAGs), and all public metagenomes resulted in hits which were subsequently aligned against the
934 generated HMM profiles. After selecting gene arrays that have all five complete or nearly complete
935 genes, we identified 6,964 arrays in public genomes and 5,000 arrays in public metagenomes.
936 Aligned sequences for all proteins from the same array were concatenated, and the resulting
937 sequences were dereplicated with cd-hit (Huang et al., 2010) at 90% identity, aligned over at least
938 90% of the shorter sequences. This resulted in 2851 clusters, 1799 from metagenomes and 1052
939 from genomes. Whereas the alignment of the Cas8e proteins from these clusters showed high

940 variability, the predicted L1 helix regions of the Cas8e, which have been shown to directly interact
941 with the PAM (Xiao et al., 2017), presented higher conservation. We generated a list with the L1
942 signatures from the dereplicated cluster set and we subsequently manually filtered out systems
943 that do not belong to known cultured mesophilic bacteria (**Table S3**). From the resulting list we
944 selected I-E CRISPR/Cas systems with a variety of L1 motifs for experimental validation with
945 PAM-DETECT.

946

947 **Comparative analysis of I-B CAST transposases**

948 We searched previous literature (Peters et al., 2017; Saito et al., 2021) for *in silico* identified I-B2
949 CASTs, which contain a fused *tnsAB* gene and are easily distinguished from I-B1 CASTs, which
950 contain separate *tnsA* and *tnsB* genes. We observed that one clade of the I-B2 CASTs
951 encompasses systems with *tnsAB-tnsC-tnsD* operons while having the *tniQ* gene separated,
952 whereas the other clade encompasses systems with *tnsAB-tnsC-tniQ* operons and the *tnsD* gene
953 separated. We denoted the systems in the former clade as I-B2.1 CASTs and in the latter clade
954 as I-B2.2 CASTs. We focused on the I-B2.2 CAST clade, that has no *in vitro* or *in vivo*
955 characterized members, and we discarded from further analysis the systems that lacked at least
956 one of the CRISPR-Cas or transposition genes (*tnsAB*, *tnsC*, *tnsD*, *tniQ*, *cas5*, *cas6*, *cas7*, *cas8*).
957 We performed BlastP search (Altschul et al., 1990) using the TnsAB, TnsC, TnsD, TniQ proteins
958 of each selected I-B2.2 system as queries, aiming to identify additional I-B2.2 CAST candidates.
959 Our analysis yielded in total seven I-B2.2 systems and we selected six previously described I-
960 B2.1 systems for phylogenetic analysis (Saito et al., 2021). The alignment of I-B2.1 and I-B2.2
961 transposition proteins was performed using T-Coffee (Di Tommaso et al., 2011), the phylogenetic
962 trees were built using average distance and the BLOSUM62 matrix and they were visualized with
963 JalView (Waterhouse et al., 2009).

964

965 ***In silico* analysis of RoCAST**

966 We predicted the CRISPR array of RoCAST by uploading the *Rippkaea orientalis* genomic region
967 between the *Rocas5* and *RotniQ* to CRISPRFinder (Grissa et al., 2007). The RoCAST ends were
968 determined manually on Benchling by searching for repeat sequences of 20 nucleotides, with
969 maximum 5 mismatched nucleotides, within the *Rippkaea orientalis* genomic regions 1 kb
970 upstream of the *R. orientalis tnsAB* and 1 kb downstream of the *RotnsD*. We identified two types
971 of repeat sequences present in both regions in opposite orientations and a candidate duplication
972 region. Notably, we identified five repeat sequences in the predicted left end region, with one of
973 the repeat sequences located downstream of the predicted duplication site, hence outside of the
974 predicted RoCAST limits. The TXTL transposition demonstrated that this repeat is not part of the
975 RoCAST transposon.

976 REFERENCES

- 977 Almendros, C., Guzmán, N.M., Díez-Villaseñor, C., García-Martínez, J., and Mojica, F.J.M.
978 (2012). Target motifs affecting natural immunity by a constitutive CRISPR-Cas system in
979 *Escherichia coli*. PLoS One 7, e50797.
- 980 Altschul, S.F., Gish, W., Miller, W., Myers, E.W., and Lipman, D.J. (1990). Basic local alignment
981 search tool. J. Mol. Biol. 215, 403–410.
- 982 Barrangou, R., and Doudna, J.A. (2016). Applications of CRISPR technologies in research and
983 beyond. Nature Biotechnology 34, 933–941.
- 984 Caliando, B.J., and Voigt, C.A. (2015). Targeted DNA degradation using a CRISPR device
985 stably carried in the host genome. Nat. Commun. 6, 1–10.
- 986 Collias, D., and Beisel, C.L. (2021). CRISPR technologies and the search for the PAM-free
987 nuclease. Nat. Commun. 12, 1–12.
- 988 Davidson, A.R., Lu, W.-T., Stanley, S.Y., Wang, J., Mejdani, M., Trost, C.N., Hicks, B.T., Lee, J.,
989 and Sontheimer, E.J. (2020). Anti-CRISPRs: protein inhibitors of CRISPR-Cas systems. Annu.
990 Rev. Biochem. 89, 309–332.
- 991 Di Tommaso, P., Moretti, S., Xenarios, I., Orobítg, M., Montanyola, A., Chang, J.-M., Taly, J.-F.,
992 and Notredame, C. (2011). T-Coffee: a web server for the multiple sequence alignment of
993 protein and RNA sequences using structural information and homology extension. Nucleic Acids
994 Res. 39, W13–W17.
- 995 Eddy, S.R. (2009). A new generation of homology search tools based on probabilistic inference.
996 Genome Inform. 23, 205–211.
- 997 Edgar, R., Domrachev, M., and Lash, A.E. (2002). Gene Expression Omnibus: NCBI gene
998 expression and hybridization array data repository. Nucleic Acids Res. 30, 207–210.
- 999 Enright, A.J., Van Dongen, S., and Ouzounis, C.A. (2002). An efficient algorithm for large-scale
1000 detection of protein families. Nucleic Acids Res. 30, 1575–1584.
- 1001 Fineran, P.C., Gerritzen, M.J.H., Suárez-Diez, M., Künne, T., Boekhorst, J., van Hijum, S.A.F.T.,
1002 Staals, R.H.J., and Brouns, S.J.J. (2014). Degenerate target sites mediate rapid primed
1003 CRISPR adaptation. Proc. Natl. Acad. Sci. U. S. A. 111, E1629–E1638.
- 1004 Fu, B.X.H., Wainberg, M., Kundaje, A., and Fire, A.Z. (2017). High-throughput characterization
1005 of Cascade type I-E CRISPR guide efficacy reveals unexpected PAM diversity and target
1006 sequence preferences. Genetics 206, 1727–1738.
- 1007 Garamella, J., Marshall, R., Rustad, M., and Noireaux, V. (2016). The All *E. coli* TX-TL Toolbox
1008 2.0: A platform for cell-free synthetic biology. ACS Synth. Biol. 5, 344–355.
- 1009 Gasiunas, G., Young, J.K., Karvelis, T., Kazlauskas, D., Urbaitis, T., Jasnauskaitė, M., Grusyte,
1010 M.M., Paulraj, S., Wang, P.-H., Hou, Z., et al. (2020). A catalogue of biochemically diverse
1011 CRISPR-Cas9 orthologs. Nat. Commun. 11, 5512.
- 1012 Gomaa, A.A., Klumpe, H.E., Luo, M.L., Selle, K., Barrangou, R., and Beisel, C.L. (2014).

- 1013 Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems.
1014 mBio 5, e00928–13.
- 1015 Grissa, I., Vergnaud, G., and Pourcel, C. (2007). CRISPRFinder: a web tool to identify clustered
1016 regularly interspaced short palindromic repeats. Nucleic Acids Res. 35, W52–W57.
- 1017 Hidalgo-Cantabrana, C., and Barrangou, R. (2020). Characterization and applications of Type I
1018 CRISPR-Cas systems. Biochem. Soc. Trans. 48, 15–23.
- 1019 Hochstrasser, M.L., Taylor, D.W., Kornfeld, J.E., Nogales, E., and Doudna, J.A. (2016). DNA
1020 targeting by a minimal CRISPR RNA-guided Cascade. Mol. Cell 63, 840–851.
- 1021 Huang, Y., Niu, B., Gao, Y., Fu, L., and Li, W. (2010). CD-HIT Suite: a web server for clustering
1022 and comparing biological sequences. Bioinformatics 26, 680–682.
- 1023 Huo, Y., Nam, K.H., Ding, F., Lee, H., Wu, L., Xiao, Y., Farchione, M.D., Jr, Zhou, S.,
1024 Rajashankar, K., Kurinov, I., et al. (2014). Structures of CRISPR Cas3 offer mechanistic insights
1025 into Cascade-activated DNA unwinding and degradation. Nat. Struct. Mol. Biol. 21, 771–777.
- 1026 Jiao, C., Sharma, S., Dugar, G., Peeck, N.L., Bischler, T., Wimmer, F., Yu, Y., Barquist, L.,
1027 Schoen, C., Kurzai, O., et al. (2021). Noncanonical crRNAs derived from host transcripts enable
1028 multiplexable RNA detection by Cas9. Science 372, 941–948.
- 1029 Jore, M.M., Lundgren, M., van Duijn, E., Bultema, J.B., Westra, E.R., Waghmare, S.P.,
1030 Wiedenheft, B., Pul, U., Wurm, R., Wagner, R., et al. (2011). Structural basis for CRISPR RNA-
1031 guided DNA recognition by Cascade. Nat. Struct. Mol. Biol. 18, 529–536.
- 1032 Karvelis, T., Gasiunas, G., Young, J., Bigelyte, G., Silanskas, A., Cigan, M., and Siksnys, V.
1033 (2015). Rapid characterization of CRISPR-Cas9 protospacer adjacent motif sequence elements.
1034 Genome Biol. 16, 1–13.
- 1035 Khakimzhan, A., Garenne, D., Tickman, B., Fontana, J., Carothers, J., and Noireaux, V. (2021).
1036 Complex dependence of CRISPR-Cas9 binding strength on guide RNA spacer lengths. Phys.
1037 Biol.
- 1038 Klompe, S.E., Vo, P.L.H., Halpin-Healy, T.S., and Sternberg, S.H. (2019). Transposon-encoded
1039 CRISPR–Cas systems direct RNA-guided DNA integration. Nature 571, 219–225.
- 1040 Leenay, R.T., and Beisel, C.L. (2017). Deciphering, communicating, and engineering the
1041 CRISPR PAM. J. Mol. Biol. 429, 177–191.
- 1042 Leenay, R.T., Maksimchuk, K.R., Slotkowski, R.A., Agrawal, R.N., Gomaa, A.A., Briner, A.E.,
1043 Barrangou, R., and Beisel, C.L. (2016). Identifying and visualizing functional PAM diversity
1044 across CRISPR-Cas systems. Mol. Cell 62, 137–147.
- 1045 Li, M., Gong, L., Cheng, F., Yu, H., Zhao, D., Wang, R., Wang, T., Zhang, S., Zhou, J.,
1046 Shmakov, S.A., et al. (2021). Toxin-antitoxin RNA pairs safeguard CRISPR-Cas systems.
1047 Science 372, eabe5601.
- 1048 Liao, C., Slotkowski, R.A., Achmedov, T., and Beisel, C.L. (2019a). The *Francisella novicida*
1049 Cas12a is sensitive to the structure downstream of the terminal repeat in CRISPR arrays. RNA
1050 Biol. 16, 404–412.

- 1051 Liao, C., Ttofali, F., Slotkowski, R.A., Denny, S.R., Cecil, T.D., Leenay, R.T., Keung, A.J., and
1052 Beisel, C.L. (2019b). Modular one-pot assembly of CRISPR arrays enables library generation
1053 and reveals factors influencing crRNA biogenesis. *Nat. Commun.* *10*, 2948.
- 1054 Liu, T., Pan, S., Li, Y., Peng, N., and She, Q. (2018). Type III CRISPR-Cas system: introduction
1055 and its application for genetic manipulations. *Curr. Issues Mol. Biol.* *26*, 1–14.
- 1056 Makarova, K.S., Wolf, Y.I., Alkhnbashi, O.S., Costa, F., Shah, S.A., Saunders, S.J., Barrangou,
1057 R., Brouns, S.J.J., Charpentier, E., Haft, D.H., et al. (2015). An updated evolutionary
1058 classification of CRISPR–Cas systems. *Nat. Rev. Microbiol.* *13*, 722–736.
- 1059 Makarova, K.S., Wolf, Y.I., Iranzo, J., Shmakov, S.A., Alkhnbashi, O.S., Brouns, S.J.J.,
1060 Charpentier, E., Cheng, D., Haft, D.H., Horvath, P., et al. (2019). Evolutionary classification of
1061 CRISPR–Cas systems: a burst of class 2 and derived variants. *Nat. Rev. Microbiol.* *18*, 67–83.
- 1062 Marino, N.D., Zhang, J.Y., Borges, A.L., Sousa, A.A., Leon, L.M., Rauch, B.J., Walton, R.T.,
1063 Berry, J.D., Joung, J.K., Kleinstiver, B.P., et al. (2018). Discovery of widespread type I and type
1064 V CRISPR-Cas inhibitors. *Science* *362*, 240–242.
- 1065 Marshall, R., Maxwell, C.S., Collins, S.P., Jacobsen, T., Luo, M.L., Begemann, M.B., Gray, B.N.,
1066 January, E., Singer, A., He, Y., et al. (2018). Rapid and scalable characterization of CRISPR
1067 technologies using an *E. coli* cell-free transcription-translation system. *Mol. Cell* *69*, 146–
1068 157.e3.
- 1069 Maxwell, C.S., Jacobsen, T., Marshall, R., Noireaux, V., and Beisel, C.L. (2018). A detailed cell-
1070 free transcription-translation-based assay to decipher CRISPR protospacer-adjacent motifs.
1071 *Methods* *143*, 48–57.
- 1072 Mulepati, S., and Bailey, S. (2013). *In vitro* reconstitution of an *Escherichia coli* RNA-guided
1073 immune system reveals unidirectional, ATP-dependent degradation of DNA target. *J. Biol.*
1074 *Chem.* *288*, 22184–22192.
- 1075 Musharova, O., Sitnik, V., Vlot, M., Savitskaya, E., Datsenko, K.A., Krivoy, A., Fedorov, I.,
1076 Semenova, E., Brouns, S.J.J., and Severinov, K. (2019). Systematic analysis of Type I-E
1077 *Escherichia coli* CRISPR-Cas PAM sequences ability to promote interference and primed
1078 adaptation. *Mol. Microbiol.* *111*, 1558–1570.
- 1079 Neuwald, A.F., and Liu, J.S. (2004). Gapped alignment of protein sequence motifs through
1080 Monte Carlo optimization of a hidden Markov model. *BMC Bioinformatics* *5*.
- 1081 Pausch, P., Müller-Esparza, H., Gleditsch, D., Altegoer, F., Randau, L., and Bange, G. (2017).
1082 Structural variation of Type I-F CRISPR RNA guided DNA surveillance. *Mol. Cell* *67*, 622–
1083 632.e4.
- 1084 Pei, J., Kim, B.-H., and Grishin, N.V. (2008). PROMALS3D: a tool for multiple protein sequence
1085 and structure alignments. *Nucleic Acids Res.* *36*, 2295–2300.
- 1086 Petassi, M.T., Hsieh, S.-C., and Peters, J.E. (2020). Guide RNA categorization enables target
1087 site choice in Tn7-CRISPR-Cas transposons. *Cell* *183*, 1757–1771.e18.
- 1088 Peters, J.E., Makarova, K.S., Shmakov, S., and Koonin, E.V. (2017). Recruitment of CRISPR-
1089 Cas systems by Tn7-like transposons. *Proc. Natl. Acad. Sci. U. S. A.* *114*, E7358–E7366.

- 1090 Pickar-Oliver, A., and Gersbach, C.A. (2019). The next generation of CRISPR–Cas
1091 technologies and applications. *Nat. Rev. Mol. Cell Biol.* *20*, 490–507.
- 1092 Rao, C., Chin, D., and Ensminger, A.W. (2017). Priming in a permissive type IC CRISPR–Cas
1093 system reveals distinct dynamics of spacer acquisition and loss. *RNA* *23*, 1525–1538.
- 1094 Rauch, B.J., Silvis, M.R., Hultquist, J.F., Waters, C.S., McGregor, M.J., Krogan, N.J., and
1095 Bondy-Denomy, J. (2017). Inhibition of CRISPR-Cas9 with bacteriophage proteins. *Cell* *168*,
1096 150–158.e10.
- 1097 Rollins, M.F., Schuman, J.T., Paulus, K., Bukhari, H.S.T., and Wiedenheft, B. (2015).
1098 Mechanism of foreign DNA recognition by a CRISPR RNA-guided surveillance complex from
1099 *Pseudomonas aeruginosa*. *Nucleic Acids Res.* *43*, 2216–2222.
- 1100 Saito, M., Ladha, A., Strecker, J., Faure, G., Neumann, E., Altae-Tran, H., Macrae, R.K., and
1101 Zhang, F. (2021). Dual modes of CRISPR-associated transposon homing. *Cell* *184*, 2441–
1102 2453.e18.
- 1103 Shin, J., and Noireaux, V. (2012). An *E. coli* cell-free expression toolbox: application to synthetic
1104 gene circuits and artificial cells. *ACS Synth. Biol.* *1*, 29–41.
- 1105 Silas, S., Lucas-Elio, P., Jackson, S.A., Aroca-Crevillén, A., Hansen, L.L., Fineran, P.C., Fire,
1106 A.Z., and Sánchez-Amat, A. (2017). Type III CRISPR-Cas systems can provide redundancy to
1107 counteract viral escape from type I systems. *Elife* *6*, e27601.
- 1108 Silverman, A.D., Karim, A.S., and Jewett, M.C. (2020). Cell-free gene expression: an expanded
1109 repertoire of applications. *Nat. Rev. Genet.* *21*, 151–170.
- 1110 Sinkunas, T., Gasiunas, G., Waghmare, S.P., Dickman, M.J., Barrangou, R., Horvath, P., and
1111 Siksnys, V. (2013). *In vitro* reconstitution of Cascade-mediated CRISPR immunity in
1112 *Streptococcus thermophilus*. *EMBO J.* *32*, 385–394.
- 1113 Stern, A., Keren, L., Wurtzel, O., Amitai, G., and Sorek, R. (2010). Self-targeting by CRISPR:
1114 gene regulation or autoimmunity? *Trends Genet.* *26*, 335–340.
- 1115 Strecker, J., Ladha, A., Gardner, Z., Schmid-Burgk, J.L., Makarova, K.S., Koonin, E.V., and
1116 Zhang, F. (2019). RNA-guided DNA insertion with CRISPR-associated transposases. *Science*
1117 *365*, 48–53.
- 1118 Tay, M., Liu, S., and Yuan, Y.A. (2015). Crystal structure of *Thermobifida fusca* Cse1 reveals
1119 target DNA binding site. *Protein Sci.* *24*, 236–245.
- 1120 Tuminauskaite, D., Norkunaite, D., Fiodorovaite, M., Tumas, S., Songailiene, I., Tamulaitiene,
1121 G., and Sinkunas, T. (2020). DNA interference is controlled by R-loop length in a type I-F1
1122 CRISPR-Cas system. *BMC Biol.* *18*, 65.
- 1123 Vercoe, R.B., Chang, J.T., Dy, R.L., Taylor, C., Gristwood, T., Clulow, J.S., Richter, C.,
1124 Przybilski, R., Pitman, A.R., and Fineran, P.C. (2013). Cytotoxic chromosomal targeting by
1125 CRISPR/Cas systems can reshape bacterial genomes and expel or remodel pathogenicity
1126 islands. *PLoS Genet.* *9*, e1003454.
- 1127 Vo, P.L.H., Ronda, C., Klompe, S.E., Chen, E.E., Acree, C., Wang, H.H., and Sternberg, S.H.
1128 (2021). CRISPR RNA-guided integrases for high-efficiency, multiplexed bacterial genome

- 1129 engineering. *Nat. Biotechnol.* **39**, 480–489.
- 1130 Wandera, K.G., Collins, S.P., Wimmer, F., Marshall, R., Noireaux, V., and Beisel, C.L. (2020).
1131 An enhanced assay to characterize anti-CRISPR proteins using a cell-free transcription-
1132 translation system. *Methods* **172**, 42–50.
- 1133 Waterhouse, A.M., Procter, J.B., Martin, D.M.A., Clamp, M., and Barton, G.J. (2009). Jalview
1134 Version 2--a multiple sequence alignment editor and analysis workbench. *Bioinformatics* **25**,
1135 1189–1191.
- 1136 Watters, K.E., Fellmann, C., Bai, H.B., Ren, S.M., and Doudna, J.A. (2018). Systematic
1137 discovery of natural CRISPR-Cas12a inhibitors. *Science* **362**, 236–239.
- 1138 Westra, E.R., van Erp, P.B.G., Künne, T., Wong, S.P., Staals, R.H.J., Seegers, C.L.C., Bollen,
1139 S., Jore, M.M., Semenova, E., Severinov, K., et al. (2012). CRISPR immunity relies on the
1140 consecutive binding and degradation of negatively supercoiled invader DNA by Cascade and
1141 Cas3. *Mol. Cell* **46**, 595–605.
- 1142 Wimmer, F., and Beisel, C.L. (2019). CRISPR-Cas systems and the paradox of self-targeting
1143 spacers. *Front. Microbiol.* **10**, 3078.
- 1144 Xiao, Y., Luo, M., Hayes, R.P., Kim, J., Ng, S., Ding, F., Liao, M., and Ke, A. (2017). Structure
1145 basis for directional R-loop formation and substrate handover mechanisms in type I CRISPR-
1146 Cas system. *Cell* **170**, 48–60.e11.
- 1147 Xue, C., Seetharam, A.S., Musharova, O., Severinov, K., Brouns, S.J.J., Severin, A.J., and
1148 Sashital, D.G. (2015). CRISPR interference and priming varies with individual spacer
1149 sequences. *Nucleic Acids Res.* **43**, 10831–10847.
- 1150 Yin, Y., Yang, B., and Entwistle, S. (2019). Bioinformatics identification of anti-CRISPR loci by
1151 using homology, guilt-by-association, and CRISPR self-targeting spacer approaches. *mSystems*
1152 **4**, e00455–19.
- 1153 Zetsche, B., Abudayyeh, O.O., Gootenberg, J.S., Scott, D.A., and Zhang, F. (2020). A survey of
1154 genome editing activity for 16 Cas12a orthologs. *Keio J. Med.* **69**, 59–65.
- 1155 Zheng, Y., Han, J., Wang, B., Hu, X., Li, R., Shen, W., Ma, X., Ma, L., Yi, L., Yang, S., et al.
1156 (2019). Characterization and repurposing of the endogenous Type I-F CRISPR–Cas system of
1157 *Zymomonas mobilis* for genome engineering. *Nucleic Acids Research* **47**, 11461–11475.
- 1158 Zheng, Y., Li, J., Wang, B., Han, J., Hao, Y., Wang, S., Ma, X., Yang, S., Ma, L., Yi, L., et al.
1159 (2020). Endogenous Type I CRISPR-Cas: from foreign DNA defense to prokaryotic engineering.
1160 *Front Bioeng Biotechnol* **8**, 62.